Skip to main content

Advertisement

SpringerLink
Log in

A systematic review of matrix metalloproteinase 9 as a biomarker of survival in patients with osteosarcoma

  • Research Article
  • Published:
Tumor Biology

Abstract

Matrix metalloproteinase 9 (MMP-9) plays an important role in the progression of several types of cancer by increasing tumor growth, migration, invasion, and metastasis and is associated with poor disease prognosis. The possible prognostic value of MMP-9 in osteosarcoma has also been examined, but due to inconsistent results between studies, it has not been possible to draw firm conclusions. To clarify this issue, we conducted a meta-analysis of published studies to provide a comprehensive evaluation of the effect of high MMP-9 expression on the survival outcomes of osteosarcoma patients. Seven studies with a total of 339 patients with osteosarcoma were examined. The pooled odds ratio (OR) with corresponding 95 % confidence interval (95 % CI) was calculated to evaluate the effect of MMP-9 expression on overall survival. Meta-analysis showed that patients with high MMP-9 expression were significantly associated with lower overall survival when compared to their counterparts with low or undetectable MMP-9 expression (OR = 6.13, 95 % CI 3.45–10.89, P < 0.001). Sensitivity analysis suggested the pooled OR was stable and not significantly changed when a single study was removed. The results from the systematic review and meta-analysis show that MMP-9 is an effective biomarker for predicting survival of patients with osteosarcoma.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2
Fig. 3

Similar content being viewed by others

References

  1. Geller DS, Gorlick R. Osteosarcoma: a review of diagnosis, management, and treatment strategies. Clin Adv Hematol Oncol H O. 2010;8(10):705–18.

    PubMed  Google Scholar 

  2. Kobayashi E, Hornicek FJ, Duan Z. MicroRNA involvement in osteosarcoma. Sarcoma. 2012;2012:359739.

    Article  PubMed Central  PubMed  Google Scholar 

  3. Hameed M, Dorfman H. Primary malignant bone tumors—recent developments. Semin Diagn Pathol. 2011;28(1):86–101.

    Article  PubMed  Google Scholar 

  4. Weeden S, Grimer RJ, Cannon SR, Taminiau AH, Uscinska BM. The effect of local recurrence on survival in resected osteosarcoma. Eur J Cancer (Oxford, England: 1990). 2001;37(1):39–46.

    Article  CAS  Google Scholar 

  5. Harting MT, Blakely ML, Jaffe N, Cox Jr CS, Hayes-Jordan A, Benjamin RS, et al. Long-term survival after aggressive resection of pulmonary metastases among children and adolescents with osteosarcoma. J Pediatr Surg. 2006;41(1):194–9.

    Article  PubMed  Google Scholar 

  6. Nagase H, Visse R, Murphy G. Structure and function of matrix metalloproteinases and TIMPs. Cardiovasc Res. 2006;69(3):562–73.

    Article  CAS  PubMed  Google Scholar 

  7. Egeblad M, Werb Z. New functions for the matrix metalloproteinases in cancer progression. Nat Rev Cancer. 2002;2(3):161–74.

    Article  CAS  PubMed  Google Scholar 

  8. Viros D, Camacho M, Zarraonandia I, Garcia J, Quer M, Vila L, et al. Prognostic role of MMP-9 expression in head and neck carcinoma patients treated with radiotherapy or chemoradiotherapy. Oral Oncol. 2013;49(4):322–5.

    Article  CAS  PubMed  Google Scholar 

  9. Vilen ST, Salo T, Sorsa T, Nyberg P. Fluctuating roles of matrix metalloproteinase-9 in oral squamous cell carcinoma. Sci World J. 2013;2013:920595.

    Article  Google Scholar 

  10. Gao XH, Yang XQ, Wang BC, Liu SP, Wang FB. Overexpression of twist and matrix metalloproteinase-9 with metastasis and prognosis in gastric cancer. APJCP. 2013;14(9):5055–60.

    PubMed  Google Scholar 

  11. Huang Y, Wang JP. Expressions of MDM2 and MMP-9 in osteosarcoma tissue and clinical significances [article in Chinese]. J Pract Oncol. 2009;23(1):35–7.

    Google Scholar 

  12. Chen L, Lin JH, Zhang S. Expression of MMP-9 and TIMP-1 and their clinical significance in osteosarcoma [article in Chinese]. Chin J Exp Surg. 2004;21(12):1522–3.

    Google Scholar 

  13. Luo XZ, Ni JD. Expression and clinical significance of MMP-9 and PCNA in osteosarcoma [article in Chinese]. J Clin Res. 2006;23(5):682–4.

    CAS  Google Scholar 

  14. Li WX, Ye ZM, Yang DS, Tao HM. The expression of vascular endothelial growth factor, matrix metalloproteinases 2, 9 in osteosarcoma [article in Chinese]. Zhejiang Med J. 2006;28(9):691–4.

    CAS  Google Scholar 

  15. Foukas AF, Deshmukh NS, Grimer RJ, Mangham DC, Mangos EG, Taylor S. Stage-IIB osteosarcomas around the knee. A study of MMP-9 in surviving tumour cells. J Bone Joint Surg Br Vol. 2002;84(5):706–11.

    Google Scholar 

  16. Kushlinsky NE, Solovyov YN, Babkina IV, Gershtein ES, Bulicheva IV. Matrix metalloproteinases 2, 7, 9 and tissue inhibitor of matrix metalloproteinase-1 in the sera of patients with bone tumors. Bull Exp Biol Med. 2010;149(2):233–5.

    Article  CAS  PubMed  Google Scholar 

  17. Uchibori M, Nishida Y, Nagasaka T, Yamada Y, Nakanishi K, Ishiguro N. Increased expression of membrane-type matrix metalloproteinase-1 is correlated with poor prognosis in patients with osteosarcoma. Int J Oncol. 2006;28(1):33–42.

    CAS  PubMed  Google Scholar 

  18. Higgins JP, Thompson SG, Deeks JJ, Altman DG. Measuring inconsistency in meta-analyses. BMJ (Clin Res ed). 2003;327(7414):557–60.

    Article  Google Scholar 

  19. Mantel N, Haenszel W. Statistical aspects of the analysis of data from retrospective studies of disease. J Natl Cancer Inst. 1959;22(4):719–48.

    CAS  PubMed  Google Scholar 

  20. DerSimonian R, Laird N. Meta-analysis in clinical trials. Control Clin Trials. 1986;7(3):177–88.

    Article  CAS  PubMed  Google Scholar 

  21. Egger M, Davey Smith G, Schneider M, Minder C. Bias in meta-analysis detected by a simple, graphical test. BMJ (Clin Res ed). 1997;315(7109):629–34.

    Article  CAS  Google Scholar 

  22. Jaffe N. Osteosarcoma: review of the past, impact on the future. The American experience. Cancer Treat Res. 2009;152:239–62.

    Article  PubMed  Google Scholar 

  23. Liotta LA, Tryggvason K, Garbisa S, Hart I, Foltz CM, Shafie S. Metastatic potential correlates with enzymatic degradation of basement membrane collagen. Nature. 1980;284(5751):67–8.

    Article  CAS  PubMed  Google Scholar 

  24. Stetler-Stevenson WG. Type IV, collagenases in tumor invasion and metastasis. Cancer Metastasis Rev. 1990;9(4):289–303.

    Article  CAS  PubMed  Google Scholar 

  25. Zhang Q-W, Liu L, Chen R, Wei Y-Q, Li P, Shi H-S, et al. Matrix metalloproteinase-9 as a prognostic factor in gastric cancer: a meta-analysis. Asian Pac J Cancer Prev. 2012;13(6):2903–8.

    Article  PubMed  Google Scholar 

  26. Song J, Su H, Zhou Y-Y, Guo L-L. Prognostic value of matrix metalloproteinase 9 expression in breast cancer patients: a meta-analysis. Asian Pac J Cancer Prev. 2013;14(3):1615–21.

    Article  PubMed  Google Scholar 

  27. Peng WJ, Zhang JQ, Wang BX, Pan HF, Lu MM, Wang J. Prognostic value of matrix metalloproteinase 9 expression in patients with non-small cell lung cancer. Clinica Chim Acta Int J Clin Chem. 2012;413(13-14):1121–6.

    Article  CAS  Google Scholar 

  28. Li CY, Yuan P, Lin SS, Song CF, Guan WY, Yuan L, et al. Matrix metalloproteinase 9 expression and prognosis in colorectal cancer: a meta-analysis. Tumour Biol J Int Soc Oncodevelopmental Biol Med. 2013;34(2):735–41.

    Article  CAS  Google Scholar 

  29. Fu HL, Shao L, Wang Q, Jia T, Li M, Yang DP. A systematic review of p53 as a biomarker of survival in patients with osteosarcoma. Tumour Biol J Int Soc Oncodevelopmental Biol Med. 2013;34(6):3817–21.

    Google Scholar 

Download references

Acknowledgement

This work was supported by grants from the National Natural Science Foundation of China (no. 81372871) and Hunan Provincial Innovation Foundation For Postgraduate (no. CX2012B096).

Conflicts of interest

None

Author information

Authors and Affiliations

  1. Department of Orthopedics, The Second Xiangya Hospital of Central South University, Changsha, 410011, China

    Hui Li, Kun Zhang, Li-hong Liu, Yurong Ouyang, Jie Bu, Hong-bin Guo & Tao Xiao

Authors
  1. Hui Li
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Kun Zhang
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Li-hong Liu
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Yurong Ouyang
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Jie Bu
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Hong-bin Guo
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Tao Xiao
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Tao Xiao.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Li, H., Zhang, K., Liu, Lh. et al. A systematic review of matrix metalloproteinase 9 as a biomarker of survival in patients with osteosarcoma. Tumor Biol. 35, 5487–5491 (2014). https://doi.org/10.1007/s13277-014-1717-3

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s13277-014-1717-3

Keywords

Search

Navigation